M\u0113s ar lepnumu pazi\u0146ojam par l\u012bguma parakst\u012b\u0161anu ar uz\u0146\u0113mumu \u201cBiotest\u201d. \u0160is l\u012bgums pie\u0161\u0137ir sabiedr\u012bbai \u201cNorameda\u201d izplat\u012b\u0161anas ties\u012bbas, kas \u013cauj tai tirgot un pieg\u0101d\u0101t \u201cBiotest\u201d farmaceitiskos produktus Lietuv\u0101, Latvij\u0101 un Igaunij\u0101.<\/p>\n
“M\u0113s esam priec\u012bgi sadarboties ar \u0161\u0101da m\u0113roga farm\u0101cijas uz\u0146\u0113mumu. Lai ar\u012b \u0161\u012b mums ir sal\u012bdzino\u0161i jauna terapeitisk\u0101 nozare, m\u0113s j\u016btamies stipri. M\u016bs saista t\u0101s pa\u0161as v\u0113rt\u012bbas: kvalit\u0101te un dro\u0161\u012bba, pa\u0161atdeve un uzman\u012bba pacientam, sac\u012bja \u201cNorameda\u201d vad\u012bt\u0101js Audrius Leiva.<\/p>\n
V\u0101cijas kapit\u0101lsabiedr\u012bba \u201cBiotest\u201d specializ\u0113jas hematolo\u0123ij\u0101 un imunolo\u0123ij\u0101. \u0160\u012b sabiedr\u012bba ir pla\u0161i paz\u012bstama vis\u0101 pasaul\u0113 k\u0101 inovatore: t\u0101 izstr\u0101d\u0101, ra\u017eo un pieg\u0101d\u0101 uz asins plazmas b\u0101zes ra\u017eotus produktus da\u017e\u0101du asins un im\u016bno slim\u012bbu \u0101rst\u0113\u0161anai. \u201cBiotest\u201d produktus izmanto c\u012b\u0146\u0101 pret t\u0101d\u0101m nopietn\u0101m slim\u012bb\u0101m k\u0101 hemofilija (apgr\u016btin\u0101ta vai piln\u012bga asins rec\u0113\u0161ana), let\u0101las infekcijas vai im\u016bnsist\u0113mas trauc\u0113jumi.<\/p>\n
“Tas, ka sabiedr\u012bba \u201cBiotest\u201d ien\u0101k Baltijas tirg\u016b, ir laba zi\u0146a visiem. Turpm\u0101k pacienti ar smag\u0101m, hronisk\u0101m slim\u012bb\u0101m var\u0113s sa\u0146emt m\u0113r\u0137tiec\u012bgu \u0101rst\u0113\u0161anu, kas \u013caus vi\u0146iem dz\u012bvot gandr\u012bz norm\u0101lu dz\u012bvi, \u201d sac\u012bja \u201cNorameda\u201d vad\u012bt\u0101js Audrius Leiva.<\/p>\n
NORAMEDA<\/p>\n
\u201cNorameda\u201d ir viens no vado\u0161ajiem farm\u0101cijas uz\u0146\u0113mumiem re\u0123ion\u0101, kura galvenais m\u0113r\u0137is ir nodro\u0161in\u0101t dro\u0161u un augstas kvalit\u0101tes z\u0101\u013cu un medic\u012bnas produktu pieg\u0101di pacientiem.<\/p>\n
Uz\u0146\u0113muma darb\u012bba ietver ar\u012b pla\u0161u pakalpojumu kl\u0101stu: no tirgus anal\u012bzes, z\u0101\u013cu re\u0123istr\u0113\u0161anas, m\u0101rketinga l\u012bdz z\u0101\u013cu importam un vairumtirdzniec\u012bbas izplat\u012b\u0161anai.<\/p>\n
Ar der\u012bgu ES Z\u0101\u013cu labas ra\u017eo\u0161anas prakses licenci sabiedr\u012bba \u201cNorameda\u201d ar\u012b sertific\u0113 un nodro\u0161ina z\u0101les ES tirg\u016b, un sniedz pakalpojumus import\u0113t\u0101jiem no tre\u0161\u0101m valst\u012bm.<\/p>\n
\u201cNorameda\u201d pied\u0101v\u0101 gandr\u012bz 300 da\u017e\u0101dus farmaceitiskos produktus, no kuriem liel\u0101k\u0101 da\u013ca ir recep\u0161u un hospit\u0101l\u0101s z\u0101les. Uz\u0146\u0113mums bezrecep\u0161u produktus p\u0101rdod ar\u012b sav\u0101s interneta aptiek\u0101s Lietuv\u0101, Latvij\u0101, Igaunij\u0101 un Polij\u0101.<\/p>\n
Lietuvas kapit\u0101lsabiedr\u012bba \u0161obr\u012bd sadarbojas ar 32 partneriem no 17 pasaules valst\u012bm. \u201cNorameda\u201d darb\u012bbas teritorija aptver 9 valstis, kuru kop\u0113j\u0101 farm\u0101cijas tirgus v\u0113rt\u012bba ir 13,9 miljardi eiro.<\/p>\n","protected":false},"excerpt":{"rendered":"
M\u0113s ar lepnumu pazi\u0146ojam par l\u012bguma parakst\u012b\u0161anu ar uz\u0146\u0113mumu \u201cBiotest\u201d. \u0160is l\u012bgums pie\u0161\u0137ir sabiedr\u012bbai \u201cNorameda\u201d izplat\u012b\u0161anas ties\u012bbas, kas \u013cauj tai tirgot un pieg\u0101d\u0101t \u201cBiotest\u201d farmaceitiskos produktus Lietuv\u0101, Latvij\u0101 un Igaunij\u0101. “M\u0113s esam priec\u012bgi sadarboties ar \u0161\u0101da m\u0113roga farm\u0101cijas uz\u0146\u0113mumu. Lai ar\u012b \u0161\u012b mums ir sal\u012bdzino\u0161i jauna terapeitisk\u0101 nozare, m\u0113s j\u016btamies stipri. M\u016bs saista t\u0101s pa\u0161as […]<\/p>\n","protected":false},"author":220,"featured_media":6703,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_links_to":"","_links_to_target":""},"categories":[141],"tags":[],"_links":{"self":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/6913"}],"collection":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/users\/220"}],"replies":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/comments?post=6913"}],"version-history":[{"count":1,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/6913\/revisions"}],"predecessor-version":[{"id":6918,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/posts\/6913\/revisions\/6918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/media\/6703"}],"wp:attachment":[{"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/media?parent=6913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/categories?post=6913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.norameda.com\/lv\/wp-json\/wp\/v2\/tags?post=6913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}